Literature DB >> 4017422

Felodipine kinetics in healthy men.

B Edgar, C G Regårdh, G Johnsson, L Johansson, P Lundborg, I Löfberg, O Rönn.   

Abstract

In a randomized, crossover study, the absorption, distribution, and elimination of intravenous and oral felodipine were investigated in eight healthy men 22 to 31 years old. Felodipine was given as a 2.5 mg iv infusion over 30 minutes and as a 27.5 mg oral solution. Both doses were labeled with 25 microCi 14C-felodipine. Given as an oral solution, felodipine is rapidly (mean time to peak concentration 64 minutes; range 30 to 90 minutes) and completely absorbed. Presystemic elimination reduced the availability to 16% (range 10% to 25%). Felodipine kinetics can be described by a multicompartmental model with three distinct phases. The t1/2 for the initial phase was 6.4 minutes (range 1.7 to 10.4 minutes) and felodipine was distributed to a volume of 0.6 L/kg (range 0.4 to 0.9 L/kg), which approximately corresponds to the total body water. The second distribution phase reached pseudoequilibrium with a t1/2 of 1.6 hours (range 1.3 to 2.2 hours). The volume of distribution at the end of this phase was 9.7 L/kg (range 6.0 to 18.2 L/kg). The terminal phase had t1/2 of 10.2 hours (range 6.7 to 20.7 hours). The contribution of the three phases to the AUC was 15%, 40%, and 45% in the order of increased t1/2. Total body clearance of felodipine was 1.2 L/min (range 0.9 to 1.6 L/min). Within 72 hours after drug dosing, 62% to 81% of the felodipine doses were excreted in the urine and feces as metabolites. The rate of excretion by the kidneys had a biphasic pattern, with t1/2 values of 4 and 18 hours. Approximately 10% of the doses was excreted in the feces.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4017422     DOI: 10.1038/clpt.1985.160

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  41 in total

1.  A population study of the pharmacokinetics of felodipine.

Authors:  E Blychert; B Edgar; D Elmfeldt; T Hedner
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Authors:  Hayley S Brown; Kiyomi Ito; Aleksandra Galetin; J Brian Houston
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

4.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

Review 5.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

6.  Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.

Authors:  E Blychert; K Wingstrand; B Edgar; K Lidman
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 7.  Towards quantitative prediction of oral drug absorption.

Authors:  Jennifer B Dressman; Kirstin Thelen; Ekarat Jantratid
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 9.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 10.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.